Apogee Therapeutics, Inc.
APGE
Rank in Stocks
#2347
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Share Price
$135.07
Last synced: 2026-09-04
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
137.21%
Country
US
Trade Apogee Therapeutics, Inc. (APGE)
Category
Healthcare
P/B ratio for Apogee Therapeutics, Inc. (APGE)
P/B ratio as of October 2026 TTM: 8.53
According to Apogee Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 8.53. At the end of 2023 the company had a P/B ratio of 3.73.
P/B ratio history for Apogee Therapeutics, Inc. from 2022 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
